EGFR and non-small cell lung carcinoma: In the Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study), both MET-IHC 3 or higher and positive METamp (fluorescence in situ hybridization [FISH] gene copy number [GCN] ≥ 5) predicted the superiority of combination treatments (gefitinib plus tepotinib) over chemotherapy.16